Skip to main content
SpringerLink
Log in

Phase II trial of merbarone in soft tissue sarcoma

A Southwest Oncology Group study

  • Brief Report
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

Thirty-seven patients with advanced soft tissue sarcoma were treated with merbarone utilizing a daily intravenous schedule for five days. Only one partial response was observed in the thirty-three evaluable patients. The major toxicities were renal, with elevation of creatinine and/or proteinuria, and gastrointestinal, with mild to moderate nausea and vomiting. Merbarone in this dose and schedule has minimal activity in soft tissue sarcoma.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Brewer AD, Minatelli JA, Plowman J, Paul KD, Narayanan VL: 5-(N-phenylcarboxamido-s-thiobarbituric acid (NSC-336628). A novel potential antitumor agent. Biochem Pharmacol 34:2047–2050, 1985

    Google Scholar 

  2. Plowman J, Paul KD, Narayanan VL, Brewer AD, Minatelli JA: A novel experimental antitumor agent: 5-N-phenylcarboxamido)-2-thiobarbituric acid, NSC-336628. Proc Amer Ass Cancer Res 26:251, 1985

    Google Scholar 

  3. National Cancer Institute, clinical brochure merbarone NSC-336628, October, 1985

  4. Cooney DA, Covery JM, Kang GJ, Dala M, McMahon JB, Johns DG: Initial mechanistic studies with merbarone (NSC-336628). Biochem Pharmacol 34:3395–3398, 1985

    Google Scholar 

  5. Drake FH, Hofmann GA, Mong S,et al.:In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone. Cancer Res 49:2578–2583, 1989

    Google Scholar 

  6. Dimaggio JJ, Warrell RP, Muindi J, Stevens YW, Lee SJ, Iowenthal DA, Haines I, Walsh TD, Balzer L, Yaldei S, Young CW. Phase I clinical and pharmacological study of merbarone, Cancer Res 50:1151–1155, 1990

    Google Scholar 

  7. Kraut EH, Grever MR, Staubus AE, Malspeis L: Phase I clinical trial of merbarone (NSC-336628), Abstract 760, AACR, March, 1988

  8. Chang AE, Rosenberg SA, Glatstein EJ, Antman RH, DeVita VT, Hellman S, Rosenberg SA, Lippincott JB (ed):Sarcomas of Soft Tissues in Cancer Principles and Practice of Oncology. Philadelphia 1345–1398, 1989

Download references

Author information

Authors and Affiliations

  1. The Ohio State University, Columbus, OH

    Eric H. Kraut & Stanley P. Balcerzak

  2. Southwest Oncology Group Statistical Center, Seattle, WA

    Jackie Bendetti

  3. City of Hope National Medical Center, Duarte, CA, USA

    James H. Doroshow

Authors
  1. Eric H. Kraut
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jackie Bendetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stanley P. Balcerzak
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. James H. Doroshow
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kraut, E.H., Bendetti, J., Balcerzak, S.P. et al. Phase II trial of merbarone in soft tissue sarcoma. Invest New Drugs 10, 347–349 (1992). https://doi.org/10.1007/BF00944194

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00944194

Key words

Search

Navigation